IPHA
Innate Pharma SA
$1.76
+2.92%
$165.1M
No data for this timeframe.
Vol
Market Cap$165.1M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (88%)
Inst. Holders1 funds
Inst. Value$81.2K
Inst. Activity0 buys / 1 sells
SEC Reports2
Exchange OTC·Sector Biological Products, (No Diagnostic Substances)·Inc. I0·CIK 0001598599·Prev Close $1.71
Recent Activity
May 24, 2026
SEC
HC Wainwright Upgrades IPHA to Buy — PT $5 (+173%)
ANALYST-UPGRADE — Impact 3/10
Apr 24, 2026
SEC
HC Wainwright upgrades IPHA to Buy from Neutral — PT $5 (+265%)
ANALYST-UPGRADE — Impact 2/10
Inst.
UBS Group AG — TRIM
5,957 shares ($10.8K)
Inst.
CITADEL ADVISORS LLC — DOUBLED
24,267 shares ($43.2K)
Price Targets
$6.00
+239.0% upside
Strong Buy
Current $1.77
Low $3.00
Median $6.50
High $8.00
4 analysts
$3.00
$8.00
Analyst Ratings
2Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 7, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.15 ▲ +5.6% | $-0.15 — $-0.15 | 1 | |
| Next Q | $-0.08 ▲ +10.9% | $-0.08 — $-0.08 | 1 | |
| Current FY | $-0.55 ▼ -0.9% | $-0.65 — $-0.46 | 14% YoY | 3 |
| Next FY | $-0.63 ▼ -1.1% | $-0.99 — $-0.40 | -16% YoY | 3 |
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| MORGAN STANLEY | $81.2K | — |
1 institutional holders with $81.2K total value (46,394 shares) as of 2025-Q4. Top holders: MORGAN.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | MORGAN STANLEY | 46,394 | $81.2K | 100.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| UBS Group AG | TRIM | 9,001 | 5,957 | -33.8% | $10.8K | 2025-Q2 |
| CITADEL ADVISORS LLC | DOUBLED | 11,853 | 24,267 | +104.7% | $43.2K | 2025-Q1 |
| UBS Group AG | DOUBLED | 3,510 | 9,001 | +156.4% | $16.0K | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 21,267 | 11,853 | -44.3% | $21.9K | 2024-Q4 |
| UBS Group AG | TRIM | 8,408 | 3,510 | -58.3% | $6.5K | 2024-Q4 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
2 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 0 mixed, 0 neutral. Avg impact: 2.5/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (88% buy). Based on 8 analysts: 2 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$6.00 mean target
+239.0% upside
Strong Buy (3.00)
$3.00 Low
$8.00 High
| Metric | Value |
|---|---|
| Current Price | $1.77 |
| Target Low | $3.00 |
| Target Mean | $6.00 |
| Target Median | $6.50 |
| Target High | $8.00 |
| # Analysts | 4 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-03-31 |
$-0.15 | $-0.15 | $-0.15 | — | +5.6% | 0↑ 1↓ | $0.0B | — | 1 |
| Next Q 2026-06-30 |
$-0.08 | $-0.08 | $-0.08 | — | +10.9% | 0↑ 1↓ | $0.0B | — | 1 |
| Current FY 2026-12-31 |
$-0.55 | $-0.65 | $-0.46 | 14.0% | -0.9% | 0↑ 1↓ | $0.0B | 246.6% | 3 |
| Next FY 2027-12-31 |
$-0.63 | $-0.99 | $-0.40 | -15.8% | -1.1% | 0↑ 1↓ | $0.1B | 107.4% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.152 | |
| 7d ago | $-0.161 | +0.009 |
| 30d ago | $-0.161 | +0.009 |
| 60d ago | $-0.142 | -0.010 |
| 90d ago | $-0.142 | -0.010 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 7, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| May 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Mar 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Jan 1, 2026 | 2 | 5 | 2 | 0 | 0 | 78% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 14, 2026
Clinical Trial
Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma
Phase Phase 2 — TERMINATED
May 14, 2026
Clinical Trial
Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma
Phase Phase 2 — COMPLETED